Advanced Prostate Cancer VL

Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James

Details
Nick James and Alicia Morgans discuss the quality of life and health economics data from the docetaxel part of the STAMPEDE trial. They also review data presented by Chris Parker on the use of radiotherapy to the primary tumor for men with newly-diagnosed metastatic prostate cancer. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR...

ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess

Details
(Length of Discussion: 12 min) Alicia Morgans and Earle Burgess discuss the details of the investigator-initiated trial called ENZADA. They discuss the “why” behind the design of this Phase II trial. Their desire is to understand whether or not triplicate therapy with ADT, plus docetaxel, plus a next gen endocrine agent will further improve outcome over either agent alone in this patient populatio...

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad

Details
Alicia Morgans and Fred Saad dialogue about the details of this phase 3 trial by the Quebec Cooperative Group of Radiation Oncologists in patients with high-risk localized prostate cancer. The aim of this superiority randomized trial was to compare outcomes of RT combined with either 36 or 18 months of ADT. Biographies: Fred Saad, MD FRCS Professor and Chief of Urologic Oncology, University of Mon...

Genetic Screening for Patients with Prostate Cancer - Todd Morgan

Details
Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...

IRONMAN Registry: A Global Landmark Trial in Advanced Prostate Cancer

Details
(Length of Discussion: 22 min) Alicia Morgans has a discussion with Dan George uncovering details about the IRONMAN Registry. The objective is to look globally at advanced prostate cancer, both with the metastatic and the castrate-resistant populations, seeking to understand patient outcomes and their experiences through this process. Biographies: Daniel George, MD Alicia Morgans, MD, MPH Related...

Current State of Liquid Biopsies in Prostate Cancer - Gert Attard

Details
(Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

Details
(Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...

The United States Preventive Services Task Force PSA Screening Recommendations- David Penson

Details
(Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...

Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi

Details
(Length of Discussion: 12 min) Susan Halabi, the first biostatistician to become a fellow of ASCO, discusses recent data on overall survival in prostate cancer for black versus white men with Alicia Morgans and Charles Ryan. Susan discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate canc...

Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng

Details
(Length of Discussion: 16 min) An emerging expert in the field of genetics and prostate cancer, Heather Cheng speaks with Charles Ryan in a thought-provoking dialogue of genetic evaluation and counseling for patients with prostate cancer. They review a variety of the genes that are involved in both DNA repair as well as the Lynch Syndrome, wrapping up with a discussion about PARP Inhibitors. Biogr...